Inflammation: How Much Is Too Much and Can It Be Controlled?

  • V. Rumalla
  • S. F. Lowry
Conference paper


The human immune response to infection includes an orchestration of various specific and non-specific soluble factors and cellular elements. The appropriate response leads to efficient control of infection or repair of injury; but when this response is too little or too much it may result in a completely different outcome. An attenuated immune defense leads to poor healing and prolonged infection. By contrast, an exaggerated response may result in shock and multi-system organ failure [1–3]. It is a balanced and regulated immune cascade which most predictably leads to recovery. Among the areas of most intense current interest is an understanding of the mechanics which promote such activation and control of the immune response to inflammation.


Tumor Necrosis Factor Septic Shock Tumor Necrosis Factor Receptor Adult Respiratory Distress Syndrome Tumor Necrosis Factor Production 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Davies MG, Hagen PO(1997) Systemic inflammatory response syndrome. Br J Surg 84:920PubMedGoogle Scholar
  2. 2.
    Bone RC (1996) Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome. What we do and do not know about cytokine regulation. Crit Care Med 24:163PubMedGoogle Scholar
  3. 3.
    Bone RC (1996) Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response and the multiple organ dysfunction syndrome. Ann Intern Med 125:680PubMedGoogle Scholar
  4. 4.
    Nystrom PO (1998) The systemic inflammatory response syndrome. J Antimicrob Chemother 41:A1Google Scholar
  5. 5.
    Schmand JF, Ayala A, Morrison MH, Chaudry IH (1995) Effects of hydroxyethyl starch after trauma hemorragic shock: restoration of macrophage integrity and prevention of increased circulating interleukin-6. Crit Care Med 23:806PubMedGoogle Scholar
  6. 6.
    Chaudry IH, Ayala A, Ertel W, Stephan RN (1990) Hemorrhage and resuscitation: immunological aspects. Am J Physiol 259:R663PubMedGoogle Scholar
  7. 7.
    Meldrum DR, Ayala A, Perrin MM et al (1991) Diltiazem restores IL-2, IL-3, IL-6, and IFN-gamma synthesis and decreased host susceptibility to sepsis following hemorrage. J Surg Res 51:158PubMedGoogle Scholar
  8. 8.
    Kunkel SL, Remick DG, Strieter RM, Larrick JW (1989) Mechanisms that regulate the production and effects of tumor necrosis factor alpha. Crit Rev Immunol 9:93PubMedGoogle Scholar
  9. 9.
    Michie HR, Manogue KR, Spriggs DR et al (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:3972Google Scholar
  10. 10.
    Bauss F, Droge W, Mannel DN (1988) Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun 55:1622Google Scholar
  11. 11.
    Fong Y, Lowry SF (1996) Cytokines and the cellular response to injury and infection. Scientific American, vol II: Care in the ICUGoogle Scholar
  12. 12.
    Greenfield LJ, Mulholland MW, Oldham KT, Zelenock GB, and Lillemore KD (eds) (1997) Surgery: Scientific principles and practice, 2nd edn. Lippincott-Raven, PhiladelphiaGoogle Scholar
  13. 13.
    Moser R, Schleiffenbaum B, Groscurth P et al (1989) Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 83:444PubMedGoogle Scholar
  14. 14.
    Clark RAF (1993) Basics of cutaneous wound repair. J Dermatol Surg Oncol 19:693PubMedGoogle Scholar
  15. 15.
    Salomon GD, Kasid A, Cromack DT et al (1991) The local effects of cachectin/tumor necrosis factor on wound healing. Ann Surg 214:175PubMedGoogle Scholar
  16. 16.
    Girardin E, Grau GE, Dayer JM et al (1988) Tumor necrosis factor and interleukin 1 in the serum of children with severe infectious purpura. N Engl J Med 319:397PubMedGoogle Scholar
  17. 17.
    Marks JD, Marks CB, Luce JM et al (1990) Plama tumor necrosis factor in patients with septic shock: mortality rate, incidence of adult respiratory distress syndrome. Am Rev Respir Dis 141:94PubMedGoogle Scholar
  18. 18.
    Shalaby MR, Halgunset J, Haugen OA et al (1991) Cytokine-associated tissue injury and lethality in mice: a comparative study. Clin Immunol Immunopathol 61:69PubMedGoogle Scholar
  19. 19.
    Waage A, Halstensen A, Espevik T (1987) Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355PubMedGoogle Scholar
  20. 20.
    Mustafa MM, Lebel MH, Ramilo O et al (1989) Correlation of interleukin 1 beta and cachectin concentrations in cerebrospinal fluid and outcome from bacterial menigitis. J Pediatr 115:208PubMedGoogle Scholar
  21. 21.
    Tracey KJ, Beutler B, Lowry SF et al (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470PubMedGoogle Scholar
  22. 22.
    Remick DJ, Kunkel RG, Larrick JW, Kunkel SL (1987) Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 56:583PubMedGoogle Scholar
  23. 23.
    Bevilacqua MP, Pober JS, Majeau GR et al (1986) Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 83:4533PubMedGoogle Scholar
  24. 24.
    Nawroth PP, Stern DM (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740PubMedGoogle Scholar
  25. 25.
    Strieter RM, Lynch III JP, Basha MA et al (1990) Host responses in mediating sepsis and the adult respiratory distress syndrome. Semin Respir Infect 5:233PubMedGoogle Scholar
  26. 26.
    Tracey KJ, Lowry SF, Cerami A (1988) Cachectin/TNF-alpha in the septic shock and septic adult respiratory distress syndrome. Am Rev Respir Dis 138:1377PubMedGoogle Scholar
  27. 27.
    Nachman RL, Hajjar KA, Siverstein RL, Dinarello CA (1986) Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 163:1595PubMedGoogle Scholar
  28. 28.
    Gramse M, Brevario F, Pintucci G et al (1986) Enhancement by interleukin 1 of plasminogen activator inhibitor activity in cultured human endothelial cells. Biochem Biophys Res Commun 139:720Google Scholar
  29. 29.
    Nawroth PP, Handley DA, Esmon CT et al (1986) Interleukin 1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc Natl Acad USA 83:3460Google Scholar
  30. 30.
    Loppnow H, Bil R, Hirt S et al (1998) Platelet derived interleukin 1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 91:134PubMedGoogle Scholar
  31. 31.
    Van Dam AM, Poole S, Schulzberg M et al (1998) Effects of peripheral administration of LPS on the expression of immunoreactive interleukin-1 alpha, beta, and receptor antagonist in rat brain. Ann NY Acad Sci 840:128PubMedGoogle Scholar
  32. 32.
    Lang CH, Fan J, Wogner MM et al (1998) Role of central IL-1 in regulating peripheral IGF-1 during endotoxemia and sepsis. Am J Physiol 274: R956Google Scholar
  33. 33.
    Fischer E, Marano MA, Van Zee KJ et al (1992) Interleukin 1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host response to sublethal endotoxinemia. J Clin Invest 89:1551PubMedGoogle Scholar
  34. 34.
    Ohlsson K, Bjork P, Bergenfeldt M et al (1990) Interleukin 1 receptor antagonist reduces mortality from endotoxin shock. Nature 346:550Google Scholar
  35. 35.
    Alexander HR, Doherty GM, Buresh CM et al (1991) A recombinant human receptor antagonist interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 173:1029PubMedGoogle Scholar
  36. 36.
    Barriere SL, Lowry SF (1995) An overview of mortality risk prediction in sepsis. Crit Care Med 23:376PubMedGoogle Scholar
  37. 37.
    Fong YM, Moldawer LL, Marano MA et al (1989) Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 256:R659PubMedGoogle Scholar
  38. 38.
    Cannon JG, Friedberg JS, Gelfand JA et al (1992) Circulating interleukin 1B and tumor necrosis concentrations after burn injury in humans. Crit Care Med 20:1414PubMedGoogle Scholar
  39. 39.
    Mills CD, Caldwell MD, Gann DS (1989) Evidence of plasma-mediated “window” of immunodeficiency in rats following trauma. J Clin Immunol 9:139PubMedGoogle Scholar
  40. 40.
    Browder W, Williams D, Pretus H et al (1990) Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg 211:605PubMedGoogle Scholar
  41. 41.
    Akira S, Hirano T, Taga T, Kishimoto T (1990) Biology of multifunctional cytokines: IL-6 and related molecules (IL-1, and TNF). FASEB J 4:2860PubMedGoogle Scholar
  42. 42.
    Kopf M, Baumann H, Freer G et al (1994) Impaired immune and acute phase responses in interleukin 6 deficient mice. Nature 368:339PubMedGoogle Scholar
  43. 43.
    Castell JV, Gomez-Lechon M, David M et al (1989) Interleukin-6 is the major regulator of acute phase response protein synthesis in adult human hepatocytes. FEBS 242:237Google Scholar
  44. 44.
    Gauldie J, Baumann H (1991) Cytokines and acute phase protein expression. In: Kimball EH (ed) Cytokines in inflammation. Telford Press, TorontoGoogle Scholar
  45. 45.
    Heinrich PC, Castell JV, Andus T (1990) Interleukin 6 and acute phase response. Biochem J 265:621PubMedGoogle Scholar
  46. 46.
    Fong Y, Moldawer LL, Marano M et al (1989) Endotoxemia elicits increased circulating b-IFN/IL-6 in man. J Immunol 142:2321PubMedGoogle Scholar
  47. 47.
    Hack CE, DeGroot ER, Felt-Bersma RJF et al (1989) Increased plama levels of interleukin 6 in sepsis. Blood 74:1704PubMedGoogle Scholar
  48. 48.
    Castell JV, Gomez-Lechon M, David M et al (1989) Interleukin-6 is the major regulator of acute phase response protein synthesis in adult human hepatocytes. FEBS 242:237Google Scholar
  49. 49.
    Gauldie J, Northermann W, Fey GH (1990) IL-6 function as an endocrine hormone in inflammation: Hepatocytes undergoing acute phase protein response require exogenous IL-6. J Immunol 144:3804PubMedGoogle Scholar
  50. 50.
    Calandra T, Gerain J, Heumann D et al (1991) High circulating levels of IL-6 in patients with septic shock: evolution during sepsis, prognostic value and interplay with other cytokines. Am J Med 91:23PubMedGoogle Scholar
  51. 51.
    Frieling JT, van Deuren M, Wijdenes J et al (1995) Circulating interleukin 6 receptor in patients with sepsis syndrome. J Infect Dis 17:469Google Scholar
  52. 52.
    Abraham E (1998) Cytokine modifiers: pipe dream or reality? Chest 113[Suppl 3]:224SPubMedGoogle Scholar
  53. 53.
    Tracey KJ, Yuman F, Hesse DG et al (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during letal bacteremia. Nature 330:662PubMedGoogle Scholar
  54. 54.
    Fong Y, Atracey KJ, Moldawer LL et al (1989) Antibodies to cachectin/tumor necrosis factor reduces interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 170:1627PubMedGoogle Scholar
  55. 55.
    Hinshaw LB, Emerson TE, Taylor FB et al (1992) Lethal Staphylococcus Aureus-induced shock in primates: prevention of death with anti-TNF antibody. J Trauma 33:568PubMedGoogle Scholar
  56. 56.
    Mohler K, Torrance D, Smith C et al (1993) Soluble tumor necrosis factor receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both carriers and TNF antagonists. J Immunol 151:1548PubMedGoogle Scholar
  57. 57.
    Vincent JL, Bakker J, Marecaux G et al (1992) Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Chest 101:810PubMedGoogle Scholar
  58. 58.
    Eskandri MK, Bolgos G, Miller C et al (1992) Anti-tumor necrosis antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxinemia. J Immunol 148:2724Google Scholar
  59. 59.
    Wayte J, Silva A, Krausz T, Cohen J (1993) Observations on the role of tumor necrosis factor in a murine model of shock due to Streptococcus Pyogenes. Crit Care Med 21:1207PubMedGoogle Scholar
  60. 60.
    Sawyer RG, Adams RB, May AK et al (1993) Anti-tumor necrosis factor antibody reduces mortality in the presence of antibiotic. Arch Surg 128:173Google Scholar
  61. 61.
    Reinhart K, Wiegand-Lohnert C, Grimminger F (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor monoclonal antibody fragment, MAK 195, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose ranging study. Crit Care Med 24:733PubMedGoogle Scholar
  62. 62.
    Dhainaut JFA, Vincent JL, Richard C (1995) CDP571, a humanized antibody to human necrosis factor alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on the cytokine concentrations in patients with septic shock. Crit Care Med 23:1461PubMedGoogle Scholar
  63. 63.
    Ryffel B, Mihatsch MJ (1993) TNF receptor distribution in human tissues. Int Rev Exp Pathol 34:149PubMedGoogle Scholar
  64. 64.
    Tartaglia LA, Goeddel DV (1992) Tumor necrosis factor receptor signaling: a dominant negative mutation suppresses the activation of 55 kDA tumor necrosis factor receptor. J Biol Chem 267:4304PubMedGoogle Scholar
  65. 65.
    Tartaglia LA, Pennica D, Goeddel DV (1993) Ligand passing: the 75 kDa tumor necrosis factor receptor recruits TNF signaling by the p55 TNF receptor. J Biol Chem 25:18542Google Scholar
  66. 66.
    Loetscer H, Stueber D, Banner D et al (1993) Human tumor necrosis factor alpha mutants with exclusive specificity for the 55 kd or 75 kd TNF receptors. J Biol Chem 268:26350Google Scholar
  67. 67.
    Engelman H, Aderka A, Rubinstein M et al (1989) A tumor necrosis factor binding protein purified to homogeneity from human urine protects from tumor necrosis factor toxicity. J Biol Chem 20:11974Google Scholar
  68. 68.
    Heilig B, Fiehn C, Brockhaus M et al (1993) Evaluation of soluble tumor necrosis factor receptor antibodies in patients with systemic lupus erythematosus, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 13:321PubMedGoogle Scholar
  69. 69.
    Neilson D, Kavanagh JP, Rao PN (1996) Kinetics of circulating TNF alpha and TNF soluble receptors following surgery in a clinical model of sepsis. Cytokine 8:938PubMedGoogle Scholar
  70. 70.
    Calvano SE, van der Poole T, Coyle SM et al (1996) Monocyte tumor necrosis factor levels as a predictor of risk in human sepsis. Arch Surg 131:434PubMedGoogle Scholar
  71. 71.
    Read RC (1998) Experimental therapies for sepsis directed against tumor necrosis factor. J Antimicrob Chemother 41:65PubMedGoogle Scholar
  72. 72.
    Bertini R, Delgado R, Faggioni R et al (1993) Urinary TNF-binding protein protects mice against the lethal effect of TNF and endotoxin shock. Eur Cytokine Network 4:39Google Scholar
  73. 73.
    Abraham E, Glauser MP, Butler T et al (1997) p55 Tumor necrosis factor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45–2081 Study Group. JAMA 277:1531PubMedGoogle Scholar
  74. 74.
    Van Zee KJ, Kohno T, Fischer E et al (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 89:4845PubMedGoogle Scholar
  75. 75.
    Fisher CJ Jr, Agosti JM, Opal SM et al (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697PubMedGoogle Scholar
  76. 76.
    Shimauchi H, Takayama S, Imai-Tanaka T, Okada H (1998) Balance of interleukin-1 beta and interleukin-1 receptor antagonist in human periapical lesions. J Endod 24:116PubMedGoogle Scholar
  77. 77.
    Matsukawa A, Fukumoto T, Maeda T et al (1997) Detection and characterization of II-1 receptor antagonist in tissues from healthy rabbits: II-1 receptor antagonist is probably involved in health. Cytokine 9:307PubMedGoogle Scholar
  78. 78.
    Eisenberg SP, Evans RJ, Arend WP et al (1990) Primary structure and functional expression from complementary DNA of human interleukin-1 receptor antagonist. Nature 343:341PubMedGoogle Scholar
  79. 79.
    Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP (1991) Interleukin 1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 16:10331Google Scholar
  80. 80.
    Gabay C, Smith MF, Eidlen D, Arend WP (1997) Interleukin-1 receptor antagonist is an acute phase protein. J Clin Invest 99:2813Google Scholar
  81. 81.
    Guirao X, Lowry S (1996) Biologic control of injury and inflammation: much more than too little or too late. World J Surg 20:437PubMedGoogle Scholar
  82. 82.
    Fukomoto T, Matsukawa A, Ohkawara S et al (1996) Administration of neutralizing antibody against rabbit IL-1 receptor antagonist exacerbates lipopolysaccharide induced arthritis in rabbits. Inflamm Res 45:479Google Scholar
  83. 83.
    Kasai T, Inada K, Takakuwa Y et al (1997) Anti-inflammatory cytokine levels in patients with septic shock. Res Commun Mol Pathol Phamacol 98:34Google Scholar
  84. 84.
    Dinarello CA, Wolff SM (1993) The role of IL-1 in disease. N Engl J Med 328:106PubMedGoogle Scholar
  85. 85.
    Fischer E, Van Zee KJ, Marano M et al (1992) Interleukin-1 receptor antagonist circulates in the experimental inflammation and human disease. Blood 79:2196PubMedGoogle Scholar
  86. 86.
    Slotman GJ, Quinn JV, Wry PC et al (1997) Unopposed interleukin 1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis. Ann Surg 226:77PubMedGoogle Scholar
  87. 87.
    Kusuhara H, Matsuyuki H, Okumoto T (1997) Effects of nonsteroidal anti-inflammatory drugs on interleukin-1 receptor antogonist production in cultured peripheral blood mononuclear cells. Prostaglandins 54:795PubMedGoogle Scholar
  88. 88.
    De Bont ES, de Leij LH, Okken A et al (1995) Increased plasma concentrations of interleukin 1 receptor antagonist in neonatal sepsis. Pediatr Res 37:626PubMedGoogle Scholar
  89. 89.
    Endo S, Inada K, Yamada Y et al (1996) Plasma levels of interleukin 1 receptor antagonist and severity of illness in patients with burns. J Med 27:57PubMedGoogle Scholar
  90. 90.
    Shito M, Wakabayashi G, Ueda M et al (1997) Interleukin-1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia/reperfusion in the rat. Transplantation 63:143PubMedGoogle Scholar
  91. 91.
    Colagiovanni DB, Shopp GM (1996) Evaluation of interleukin-1 receptor antagonist and tumor necrosis factor binding protein in a rodent abscess model of host resistance. Immunopharmacol Immunotoxicol 18:397PubMedGoogle Scholar
  92. 92.
    Opal SM, Fisher CJ Jr, Dhainaut J-FA et al (1997) Confirmatory interleukin 1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blinded, placebo controlled, multicenter trial. Crit Care Med 25:1115PubMedGoogle Scholar
  93. 93.
    Mantovani A, Musio M, Ghezzi P et al (1998) Regulation of inhibitory pathways of the interleukin-1 system. Ann NY Acad Sci 840:338PubMedGoogle Scholar
  94. 94.
    De Waal Malefyt R, Abrams J, Bennet B et al (1991) Interleukin-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209Google Scholar
  95. 95.
    Marie C, Pitton C, Fitting C, Cavaillon JM (1996) IL-10 and IL-4 synergize with TNF alpha to induce IL-Ira production by human neutrophils. Cytokine 8:147PubMedGoogle Scholar
  96. 96.
    Marchant A, Deviere B, Byl B et al (1994) Interleukin 10 production during septicemia. Lancet 343:707PubMedGoogle Scholar
  97. 97.
    Derkx B, Marchant M, Goldman R et al (1995) High levels of interleukin 10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 171:229PubMedGoogle Scholar
  98. 98.
    Parsons PE, Moss M, Vannice JL et al (1997) Circulating Il-lra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at risk patients. Am J Respir Crit Care Med 155:1469PubMedGoogle Scholar
  99. 99.
    Marchant A, Bruyns C, Vandenabelle P et al (1994) IL-10 controls IFN-gamma and TNF production by activated macrophages. Eur J Immunol 24:1167PubMedGoogle Scholar
  100. 100.
    Rogy MA, Auffenberg T, Espat NJ et al (1995) Human tumor necrosis factor receptor and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J Exp Med 181:2289PubMedGoogle Scholar
  101. 101.
    Marchant A, Vincent JL, Goldman M (1996) Interleukin 10 as a protective cytokine produced during sepsis. In: Morrison DC, Ryan JL (eds) Novel strategies in the treatment of sepsis, pp 301–311Google Scholar
  102. 102.
    Han J, Thompson FS, Beutler B (1990) Dexamethasone and pentoxifilline inhibit endotoxin induced cachectin tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172:391PubMedGoogle Scholar
  103. 103.
    Zuckerman SH, Shellhaas J, Butler LD (1989) Differential regulation of lipopolysaccharide induced interleukin-l and tumor necrosis factor and synthesis: effects of endogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunol 19:301PubMedGoogle Scholar
  104. 104.
    Luedke CE, Cerami A (1990) Interferon gamma overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages. J Clin Invest 86:1234PubMedGoogle Scholar
  105. 105.
    Ray A, LaForge KS, Sehgal PB (1990) On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: Enhancer, TATA box, and RNA start site occlusion. Mol Cell Biol 10:5736PubMedGoogle Scholar
  106. 106.
    Brown EA, Dare HA, Marsh CB, Wewers MD (1996) The combination of endotoxin and dexamethasone induces type II interleukin-1 receptor in monocytes: a comparison to interleukin-1 beta and interleukin-1 receptor antagonist. Cytokine 8:828PubMedGoogle Scholar
  107. 107.
    Horai R, Asano M, Sudo K et al (1988) Production of mice deficient in genes for IL-1 alpha, Il-1 beta, Il-1 alpha/beta, and Il-1 receptor antagonist shows that Il-1 beta is crucial in turpentine induced fever development and glucocorticoid secretion. J Exp Med 187:1463Google Scholar
  108. 108.
    Bernton EW, Beach JE, Holaday JW et al (1997) Release of multiple hormones by direct action of interleukin 1 on pituitary cells. Science 230:519Google Scholar
  109. 109.
    Berkenbosch F, van Oers J, del Rey A et al (1987) Corticotropin-releasing factor producing neurons in the rat activated by interleukin 1. Science 238:534Google Scholar
  110. 110.
    Lumpkin MD (1987) The regulation of ACTH secretion by IL-1. Science 238:452PubMedGoogle Scholar
  111. 111.
    Sapolsky R, Rivier C, Yamamot G et al (1987) Interleukin 1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 238:522PubMedGoogle Scholar
  112. 112.
    Bernardini R, Kamilaris TC, Calogero AE et al (1990) Interactions between tumor necrosis factor alpha, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. Endocrinology 126:2876PubMedGoogle Scholar
  113. 113.
    Gwosdow AR (1995) Mechanisms of interleukin 1 induced hormone secretion from rat adrenal gland. Endocr Res 21:25PubMedGoogle Scholar
  114. 114.
    Barber AE, Coyle SM, Marano MA et al (1993) Glucocorticoid therapy alters hormonal and cytokine response to endotoxin in man. J Immunol 150:1999PubMedGoogle Scholar
  115. 115.
    Joyce DA, Steer JH, Kloda A (1996) Dexamethasone antagonizes IL-4 and IL-10 induced release of IL-1 ra by monocytes but augments IL-4, Il-10, and TGF beta induced suppression of TNF alpha release. J Interferon Cytokine Res 16:511PubMedGoogle Scholar
  116. 116.
    Sauer J, Castren M, Hopfner U et al (1996) Inhibition of lipopolysaccharide induced monocyte interleukin-1 receptor antagonist synthesis by Cortisol: involvement of mineralcorticoid receptor. J Clin Endocrinol Metab 81:73PubMedGoogle Scholar
  117. 117.
    Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 25:1095PubMedGoogle Scholar
  118. 118.
    Pastores SM, Hasko G, Vizi ES, Kvetan V (1996) Cytokine production and its manipulation by vasoactive drugs. New Horiz 4:252PubMedGoogle Scholar
  119. 119.
    Van der Poll T, Jansen J, Endert E et al (1994) Noradrenaline inhibits lipopoly saccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect Immun 62:2046PubMedGoogle Scholar
  120. 120.
    Van der Poll T, Braxton C, Coyle SM et al (1995) Effect of epinephrine on cytokine release during human endotoxemia. Surg Forum 46:102Google Scholar
  121. 121.
    Hamilton G, Hofbauer S, Hamilton B (1992) Endotoxin, TNF-α, interleukin 6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis 24:361PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1999

Authors and Affiliations

  • V. Rumalla
  • S. F. Lowry

There are no affiliations available

Personalised recommendations